secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001140361-24-045654
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government
--------------------------------------------------------------------------------

- Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.
- Net income of $1.3M ($0.02 diluted EPS) vs net loss of $0.4M in Q3 2023.
- Received $122M in procurement orders, including $112.5M from BARDA for oral TPOXX to the SNS.
- Special cash dividend of $0.60/share paid April 2024, up $0.15 from prior year.
- Exclusive license from Vanderbilt for preclinical monoclonal antibodies targeting orthopoxviruses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124045654/0001140361-24-045654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124045654/ef20038209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-045654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer